Paycom Software, Inc. (PAYC) Reaches $172.86 After 3.00% Down Move; 3 Analysts Are Bullish Five Prime Therapeutics, Inc. (FPRX) Last Week

Paycom Software, Inc. (NYSE:PAYC) Logo

The stock of Paycom Software, Inc. (NYSE:PAYC) is a huge mover today! The stock decreased 1.76% or $3.1 during the last trading session, reaching $172.86. About 425,081 shares traded. Paycom Software, Inc. (NYSE:PAYC) has risen 68.29% since February 11, 2018 and is uptrending. It has outperformed by 68.29% the S&P500. Some Historical PAYC News: 01/05/2018 – Paycom Software Sees 2Q Rev $123M-$125M; 01/05/2018 – PAYCOM SOFTWARE 1Q REV. $153.9M, EST. $151.5M; 17/04/2018 – PAYCOM SOFTWARE APPOINTS JON EVANS AS COO; 01/05/2018 – Paycom Software 1Q Adj EPS 95c; 01/05/2018 – Paycom Software 1Q EPS 70c; 01/05/2018 – Paycom Software 1Q Rev $153.9M; 25/04/2018 – Paycom to Participate in Upcoming Investor Conferences; 16/05/2018 – Sylebra Adds Pagseguro Digital Ltd., Exits Paycom Software: 13F; 01/05/2018 – Paycom Software 1Q Net $41.3M; 01/05/2018 – PAYCOM SOFTWARE 1Q ADJ EPS 95C, EST. 90CThe move comes after 8 months negative chart setup for the $9.90 billion company. It was reported on Feb, 11 by Barchart.com. We have $167.67 PT which if reached, will make NYSE:PAYC worth $297.03M less.

Among 3 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 3 analyst reports since August 20, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Wedbush on Thursday, January 17. The firm earned “Buy” rating on Monday, August 20 by Citigroup. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Outperform” rating given on Thursday, September 13 by Leerink Swann. See Five Prime Therapeutics, Inc. (NASDAQ:FPRX) latest ratings:

17/01/2019 Broker: Wedbush Old Rating: Neutral New Rating: Outperform Upgrade
13/09/2018 Broker: Leerink Swann Rating: Outperform New Target: $24 Maintain
20/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $60 New Target: $44 Maintain

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $405.37 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

More notable recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: Nasdaq.com which released: “Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? – Nasdaq” on January 24, 2019, also Seekingalpha.com with their article: “Five Prime to cut 41 jobs in restructuring – Seeking Alpha” published on January 15, 2019, Nasdaq.com published: “Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications – Nasdaq” on January 16, 2019. More interesting news about Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were released by: Seekingalpha.com and their article: “Goldman bullish on Insmed in premarket analyst action – Seeking Alpha” published on January 17, 2019 as well as Businesswire.com‘s news article titled: “Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium – Business Wire” with publication date: January 14, 2019.

Investors sentiment increased to 1.15 in Q3 2018. Its up 0.05, from 1.1 in 2018Q2. It increased, as 20 investors sold Five Prime Therapeutics, Inc. shares while 27 reduced holdings. 19 funds opened positions while 35 raised stakes. 30.25 million shares or 0.19% less from 30.31 million shares in 2018Q2 were reported. Td Asset Mngmt holds 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 24,729 shares. Bogle Inv L P De accumulated 0.14% or 136,029 shares. 36,000 are owned by State Common Retirement Fund. Sectoral Asset Mngmt stated it has 13,920 shares. Fmr Ltd Company holds 4.04 million shares. Wells Fargo And Company Mn has 228,354 shares. Metropolitan Life Communications Ny invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Great West Life Assurance Communications Can invested in 0% or 4,651 shares. Art Advsrs Ltd Liability reported 0.02% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Wellington Management Grp Limited Liability Partnership holds 4.51M shares or 0.01% of its portfolio. 18,612 were accumulated by Proshare Lc. Parametric Port Associates Limited invested in 28,105 shares. State Bank Of Montreal Can holds 0% or 237 shares in its portfolio. Platinum Mgmt Limited has invested 0.05% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

The stock increased 0.44% or $0.05 during the last trading session, reaching $11.43. About 47,071 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 47.75% since February 11, 2018 and is downtrending. It has underperformed by 47.75% the S&P500. Some Historical FPRX News: 08/05/2018 – FIVE PRIME THERAPEUTICS INC – ESTIMATES ENDING 2018 WITH APPROXIMATELY $250 MLN IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES; 19/03/2018 – Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform; 04/05/2018 – Five Prime Closes Above 50-Day Moving Average: Technicals; 14/05/2018 – Canada Pension Plan Invest Board Exits Position in Five Prime; 15/05/2018 – Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer; 10/04/2018 – FIVE PRIME TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL; 30/05/2018 – Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology; 28/03/2018 – FIVE PRIME THERAPEUTICS STARTS DOSING IN FPA150 PHASE 1 TRIAL; 13/03/2018 – FIVE PRIME THERAPEUTICS INC – BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018; 30/05/2018 – FIVE PRIME PACT TO DEVELOP IHC COMPANION DIAGNOSTIC ASSAY

Paycom Software, Inc. provides cloud human capital management software solution that is delivered as software-as-a-service for small to mid-sized companies in the United States. The company has market cap of $9.90 billion. It provides functionality and data analytics that businesses need to manage the employment life cycle from recruitment to retirement. It has a 73.87 P/E ratio. The company??s HCM solution offers a suite of applications in the areas of talent acquisition, including applicant tracking, candidate tracker, background checks, on-boarding, E-Verify, and tax credit service applications; and time and labor management, such as time and attendance, scheduling/schedule exchange, time-off requests, labor allocation, labor management reports/push reporting, and geofencing/geotracking applications.

More notable recent Paycom Software, Inc. (NYSE:PAYC) news were published by: Benzinga.com which released: “Paycom Surges But These Analysts Remain Sidelined (NYSE:PAYC) – Benzinga” on February 06, 2019, also Benzinga.com with their article: “Earnings Scheduled For February 5, 2019 – Benzinga” published on February 05, 2019, Seekingalpha.com published: “Paycom Software Soaring – Seeking Alpha” on September 04, 2018. More interesting news about Paycom Software, Inc. (NYSE:PAYC) were released by: Seekingalpha.com and their article: “Paycom Software, Inc. (PAYC) CEO Chad Richison on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” published on October 30, 2018 as well as Seekingalpha.com‘s news article titled: “Paycom Software: Growing Fast At A Stretched Valuation – Seeking Alpha” with publication date: December 11, 2018.

Among 6 analysts covering Paycom Software (NYSE:PAYC), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Paycom Software had 8 analyst reports since August 21, 2018 according to SRatingsIntel. The stock of Paycom Software, Inc. (NYSE:PAYC) has “Neutral” rating given on Wednesday, October 31 by Credit Suisse. Canaccord Genuity maintained the shares of PAYC in report on Wednesday, October 31 with “Hold” rating. The firm has “Neutral” rating given on Wednesday, September 26 by Bank of America. Barclays Capital maintained it with “Equal-Weight” rating and $151 target in Friday, September 7 report. The firm has “Overweight” rating by KeyBanc Capital Markets given on Wednesday, February 6. Canaccord Genuity downgraded the shares of PAYC in report on Monday, October 1 to “Hold” rating. The rating was maintained by Canaccord Genuity with “Hold” on Wednesday, February 6.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart